Alector reports third quarter 2023 financial results and provides business update

Achieved q4 2023 target enrollment in pivotal infront-3 phase 3 latozinemab clinical trial with 103 symptomatic ftd-grn participants
ALEC Ratings Summary
ALEC Quant Ranking